C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy

Fakhouri, 2010, C3 glomerulopathy: a new classification, Nat Rev Nephrol, 6, 494, 10.1038/nrneph.2010.85

Servais, 2012, Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, 82, 454, 10.1038/ki.2012.63

Medjeral-Thomas, 2014, C3 glomerulopathy: clinicopathologic features and predictors of outcome, Clin J Am Soc Nephrol, 9, 46, 10.2215/CJN.04700513

Bomback, 2012, Pathogenesis of the C3 glomerulopathies and reclassification of MPGN, Nat Rev Nephrol, 8, 634, 10.1038/nrneph.2012.213

D'Agati, 2012, C3 glomerulopathy: what's in a name?, Kidney Int, 82, 379, 10.1038/ki.2012.80

Hou, 2014, Toward a working definition of C3 glomerulopathy by immunofluorescence, Kidney Int, 85, 450, 10.1038/ki.2013.340

Zhang, 2012, Causes of alternative pathway dysregulation in dense deposit disease, Clin J Am Soc Nephrol, 7, 265, 10.2215/CJN.07900811

Okuda, 2015, Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children, Nephrology (Carlton), 20, 286, 10.1111/nep.12382

Rabasco, 2015, Effectiveness of mycophenolate mofetil in C3 glomerulonephritis, Kidney Int, 88, 1153, 10.1038/ki.2015.227

Caliskan, 2017, Immunosuppressive treatment in C3 glomerulopathy: is it really effective?, Am J Nephrol, 46, 96, 10.1159/000479012

Iatropoulos, 2016, Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome, Mol Immunol, 71, 131, 10.1016/j.molimm.2016.01.010

Zand, 2013, C3 glomerulonephritis associated with monoclonal gammopathy: a case series, Am J Kidney Dis, 62, 506, 10.1053/j.ajkd.2013.02.370

Chauvet, 2017, Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy, Blood, 129, 1437, 10.1182/blood-2016-08-737163

Sethi, 2012, C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up, Kidney Int, 82, 465, 10.1038/ki.2012.212

Coppo, 2014, Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments, Kidney Int, 86, 828, 10.1038/ki.2014.63

Richards, 2015, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, 17, 405, 10.1038/gim.2015.30

Goodship, 2017, Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference, Kidney Int, 91, 539, 10.1016/j.kint.2016.10.005

Pickering, 2013, C3 glomerulopathy: consensus report, Kidney Int, 84, 1079, 10.1038/ki.2013.377

Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006

Weening, 2014, The classification of glomerulonephritis in systemic lupus erythematosus revisited, J Am Soc Nephrol, 15, 241, 10.1097/01.ASN.0000108969.21691.5D

Roberts, 2009, The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility, Kidney Int, 76, 546, 10.1038/ki.2009.168

Sethi, 2016, Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN, J Am Soc Nephrol, 27, 1278, 10.1681/ASN.2015060612

Sethi, 2017, A proposal for standardized grading of chronic changes in native kidney biopsy specimens, Kidney Int, 91, 787, 10.1016/j.kint.2017.01.002